Act Now: Investor Deadline Approaching – Robbins Geller Rudman & Dowd LLP Launches Class Action Lawsuit Against Extreme Networks Inc. for Investors with Significant Losses

Act Now: Investor Deadline Approaching – Robbins Geller Rudman & Dowd LLP Launches Class Action Lawsuit Against Extreme Networks Inc. Description: SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers of Extreme Networks, Inc. (NASDAQ: EXTR) common stock between July 27, 2022, and January 30, 2024, all…

Read More

Redwire Set to Deliver Major European Satellite in Fourth Quarter, Meeting Growing International Demand

Redwire Corporation Prepares for Satellite Delivery Overview Redwire Corporation, a leading provider of space infrastructure solutions, has announced its plans to finalize the integration and delivery of two satellites for the European Space Agency’s Proba-3 mission. This mission is set to take place in the fourth quarter of this year, marking a significant milestone in…

Read More

Breaking News: Ardena Takes Big Step in US Expansion with Acquisition of Cutting-Edge Drug Manufacturing Facility from Catalent

Breaking News: Ardena Takes Big Step in US Expansion with Acquisition of Cutting-Edge Drug Manufacturing Facility from Catalent Ghent, Belgium, Oct. 14, 2024 (GLOBE NEWSWIRE) Ardena Expanding its Reach Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands, and Sweden, has made a groundbreaking move in…

Read More

Calling All Investors: Don’t Miss Out on Your Chance to Take Action Against Sprinklr Inc. with Robbins Geller Rudman & Dowd LLP!

Robbins Geller Rudman & Dowd LLP Announces Deadline for Sprinklr, Inc. Investors Background In a recent announcement, Robbins Geller Rudman & Dowd LLP stated that investors who purchased or acquired securities of Sprinklr, Inc. (NYSE: CXM) between March 29, 2023 and June 5, 2024 may be eligible to participate in a class action lawsuit. The…

Read More

Breaking News: Orion and Bayer Team Up Again to Bring Darolutamide to EU for Third Indication!

Orion Corporation Investor News 14 October 2024 at 11.00 EEST Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion’s collaboration partner Bayer has made a significant move in the field of prostate cancer treatment by submitting an application to the European Medicines Agency (EMA) for the oral androgen receptor…

Read More

Breaking News: Inventiva Secures $348 Million in Funding for Groundbreaking NATiV3 Phase 3 MASH Study!

Welcome to the Future of Medicine! Exciting News from Inventiva Daix (France), Long Island City (New York, United States), October 14, 2024 Today, Inventiva, a leading biopharmaceutical company, made a groundbreaking announcement that is set to revolutionize the world of medicine. The Company has secured a significant financing of €94.1 million, with the potential to…

Read More